Top Strike Resources Corp. d.b.a. “Vencanna Ventures Inc.” (the “Corporation”) (CSE:VENI) is pleased to provide a summary of its financial results as of July 31, 2018.
Selected financial information is outlined below and should be read in conjunction with the Corporation’s unaudited consolidated financial statements and management’s discussion and analysis for the three month period ended July 31, 2018, which are available on SEDAR at www.sedar.com.
Financial Highlights
The following table summarizes key financial highlights associated with the Corporation’s financial performance for the quarter ended July 31, 2018.
About Vencanna
On September 24, 2018, the Corporation announced the completion of a recapitalization financing, the appointment of a new management team and board of directors and commencement of trading on the Canadian Securities Exchange. The transactions have transitioned the Corporation from an oil and gas issuer to a merchant capital firm, rebranded as “Vencanna Ventures Inc.”. The recapitalized Corporation aims to be a go-to capital provider for early-stage global cannabis initiatives with an emphasis on state compliant opportunities in limited licensed jurisdictions in the United States. The Corporation looks to provide investors with a diversified, high-growth, cannabis investment strategy through strategic investments focused through-out the value chain (cultivation, processing and distribution, and including ancillary businesses).
For further information regarding this news release, please contact:
David McGorman
Chief Executive Officer and Director
Phone: (403) 351-1779
Jason Ewasuik
Vice President, Originations
Phone: (403) 992-9676
Top Strike Resources Corp.
Suite 300, 407 – 3rd Street S.W.
Calgary, AB T2P 4Z2
Source: vencanna.com
Aion Therapeutic Engages KCSA Strategic Communications as Corporate Communications Counsel
April 12 | 2021
Aion Therapeutic Inc. (CSE: AION) (” Aion Therapeutic ” or the ” Company “) today announced that it has retained KCSA Strategic Communications (” KCSA “), a leading New York City -based communications firm.
</div>
<p> KCSA will work with management to create a comprehensive, strategic communications program to lead the Company’s public and investor relations programs. Since KCSA’s inception, nearly fifty years ago, the firm has developed a strong reputation for its work representing public companies with an expertise in several verticals including the psychedelics and cannabis industries. The engagement is designed to increase the awareness and help enhance the profile of Aion Therapeutic in the marketplace. </p>
<p> “As we enter the next phase of growth for the Company, we have retained KCSA to help broaden our exposure to the investment community and to represent us in the media,” commented <span> Graham Simmonds </span> , Executive Vice Chair and CEO of Aion Therapeutic. “Our Company is at a very exciting stage and we look forward to communicating how our patented approach of utilizing psilocybin and other mushroom compounds in combination with cannabinoids to treat serious medical conditions to the global medical community.” </p>
<p> <span> Phil Carlson </span> , Managing Director of KCSA Strategic Communications, commented, “At KCSA, our professionals have an extensive history of providing expert communications and strategy for our clients. With many decades of experience, we have built a vast network in both the media and investment communities that we will proactively begin to introduce to Aion Therapeutic’s management team. We are pleased to implement this communications plan based on best practices for Aion Therapeutic.” </p>
<p> For its services supporting the Company’s public relations and investor relations efforts, KCSA will receive Usd. <span> $15,000 </span> per month. The term of the engagement will be initially six months and then ongoing on a month-to-month basis. The Company has the right to terminate the relationship with KCSA on 90 days’ notice. </p>
<p> <i> Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. </i> </p>
<p> <b> About KCSA Strategic Communications </b> </p>
<p> KCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial services, technology and healthcare. Since 1969, the firm has demonstrated strategic thinking and program execution that drive results for clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit <b> <a href="https://c212.net/c/link/?t=0&l=en&o=3125738-1&h=3052127034&u=http%3A%2F%2Fwww.kcsa.com%2F&a=www.kcsa.com" rel="nofollow noopener noreferrer" target="_blank"> www.kcsa.com </a> </b> <b> . </b> </p>
<p> <b> About Aion Therapeutic Inc. </b> </p>
<p> Aion Therapeutic Inc. through its wholly-owned subsidiary, AI Pharmaceuticals Jamaica Limited, is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, Aion Therapeutic is creating a strong international intellectual property portfolio related to its discoveries. </p>
<p> <b> DISCLAIMER & READER ADVISORY </b> </p>
<p> Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “may”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include regulatory and other third-party approvals; licensing and other risks. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein. </p>
<div id="DivAssetPlaceHolder2"> </div>
<p> SOURCE Aion Therapeutic Inc. </p>
<p> <img alt="" class="lazy" data-src="https://rt.newswire.ca/rt.gif?NewsItemId=C3315&Transmission_Id=202104120925CANADANWCANADAPR_C3315&DateId=20210412" data-srcset="" src="https://rt.newswire.ca/rt.gif?NewsItemId=C3315&Transmission_Id=202104120925CANADANWCANADAPR_C3315&DateId=20210412" srcset=""/></p>
<p> <img alt="Cision" class="lazy" data-src="https://c212.net/c/img/favicon.png?sn=C3315&sd=2021-04-12" data-srcset="" height="12" src="https://c212.net/c/img/favicon.png?sn=C3315&sd=2021-04-12" srcset="" title="Cision" width="12"/> View original content to download multimedia: <a href="http://www.newswire.ca/en/releases/archive/April2021/12/c3315.html" rel="noopener noreferrer" target="_blank"> http://www.newswire.ca/en/releases/archive/April2021/12/c3315.html </a> </p>
</div>
</div>
<p>News Provided by Canada Newswire via QuoteMedia</p>
<p></p><div class="stock-information sidebar-block">
<div class="title">Request an Investor Kit: <h3>Aion Therapeutics</h3></div>
<form action="https://investingnews.com" id="subscribe_per_category" method="POST">
<div class="form-column left">
<input name="profiles_only" type="hidden" value="yes"/><input name="subscription_form" type="hidden" value="yes"/><input name="subscribe_company_profile_form" type="hidden" value="1"/><input name="source" type="hidden" value="https://investingnews.com/news/cannabis-investing/aion-therapeutic-engages-kcsa-strategic-communications-as-corporate-communications-counsel/"/><input class="referrer" name="referral_url" type="hidden" value=""/><input name="form_name" type="hidden" value="subscribe_cprofile_use_posts"/><input class="referrer" name="referral_url" type="hidden" value=""/><input name="cprofiles[]" type="hidden" value="Tzo4OiJzdGRDbGFzcyI6NDp7czoyOiJpZCI7czozNjoiNjNjY2YxZWQtMDI4My1iNDA1LTU1YjktNWM2ZTlmNjcyNWY0IjtzOjQ6Im5hbWUiO3M6MTc6IkFpb24gVGhlcmFwZXV0aWNzIjtzOjQ6IndwaWQiO3M6OToiMTAxNDkwMTI1IjtzOjM6InVybCI7czowOiIiO30="/><input class="form-control" id="FirstName" name="first_name" placeholder="First Name" required="" type="text" value=""/><input class="form-control" id="LastName" name="last_name" placeholder="Last Name" required="" type="text" value=""/><input class="form-control" id="email" name="email" placeholder="Email" required="" type="email" value=""/><input class="form-control" id="phone" name="user_phone" pattern="[\+\s0-9]{3,15}" placeholder="Phone" title="Telephone number. Only digits and space signs are allowed" type="tel" value=""/></div>
<div class="form-column right">
<div class="extra-input">
<input id="AccreditedInvestor" name="accredited_investor" type="checkbox"/><label class="checkbox-label" for="AccreditedInvestor">
Include me in the <b>Accredited Investor</b> email list
<span class="help">
<i aria-hidden="true" class="fa fa-question-circle"></i>
<div class="help-box bigger">
Some investment opportunities are limited to accredited investors. Whether you are an accredited investor or not depends on where you live and other criteria. For full details go to https://investingnews.com/accredited-investor-definition/ or search for "accredited investor" in the search bar above.
</div>
</span>
</label>
</div>
<div class="more">
<input class="btn btn-primary" type="submit" value="Get More information"/></div>
<p class="legend">By completing this form, you are giving consent to receive communication from Aion Therapeutics using the contact information you provide. And remember you can unsubscribe at any time.</p>
</div>
</form>
</div>
Keep reading...
Show less
Trulieve Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
April 12 | 2021
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), today announced the closing of its previously announced marketed public offering of 5,000,000 subordinate voting shares in the United States and Canada (the “Offering”) at a public offering price of C$50.00 per share ( $39.63 per share after giving effect to the conversion rate published by Bloomberg at 4:30pm ET on April 7, 2021 to convert Canadian dollars to U.S. dollars). In connection with the closing of the Offering, the underwriters exercised in full their option to purchase an additional 750,000 subordinate voting shares. As a result, the gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by Trulieve, were C$287.5 million (or $227.9 million after giving effect to the conversion rate denoted above).
The Offering was conducted through a syndicate of underwriters led by Canaccord Genuity, as sole book-running manager, and included Cormark Securities Inc., as co-lead manager, as well as ATB Capital Markets Inc., Echelon Wealth Partners Inc., Eight Capital and PI Financial Corp. All of the shares in the Offering were sold by Trulieve. Trulieve intends to use the net proceeds from the Offering primarily to fund Trulieve’s business development and for general working capital purposes.
<p> A registration statement on Form S-1 relating to the Offering was filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). The Offering was made in the U.S. only by means of a prospectus included in the Registration Statement, copies of which may be obtained from: Canaccord Genuity LLC, Attention: Syndicate Department, 99 High Street, 12th Floor, <span> Boston MA </span> 02110, by email at <u> <a href="mailto:prospectus@cgf.com" rel="nofollow noopener noreferrer" target="_blank"> prospectus@cgf.com </a> </u> . The Registration Statement was also filed under the Company’s profile on SEDAR at <a href="http://www.sedar.com" rel="nofollow noopener noreferrer" target="_blank"> www.sedar.com </a> . </p>
<p> This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. </p>
<p> The subordinate voting shares were offered in all of the provinces and territories of <span> Canada </span> , other than the Province of <span> Quebec </span> , pursuant to a prospectus supplement to the Company’s short form base shelf prospectus dated <span> January 29, 2021 </span> , filed with the securities commissions or similar securities regulatory authorities in each of the provinces and territories of <span> Canada </span> . Copies of the Canadian base shelf prospectus and the prospectus supplement may be obtained from: Canaccord Genuity Corp., Attention: Syndicate Department, by email at <u> <a href="mailto:prospectus@cgf.com" rel="nofollow noopener noreferrer" target="_blank"> prospectus@cgf.com </a> </u> . Prospective investors should read the base shelf prospectus and the prospectus supplement and the other documents the Company has filed on SEDAR at www.sedar.com before making an investment decision. No securities regulatory authority has either approved or disapproved the contents of this press release. </p>
<p> <b> About Trulieve </b> </p>
<p> Trulieve is primarily a vertically integrated “seed-to-sale” company in the US, and is the first and largest fully licensed medical cannabis company in the <span> State of Florida </span> . Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the <span> State of Florida </span> , as well as directly to patients via home delivery. Trulieve also holds licenses to operate in <span> California </span> , <span> Massachusetts </span> , <span> Connecticut </span> , <span> Pennsylvania </span> and <span> West Virginia </span> . Trulieve’s subordinate voting shares are listed on the CSE under the symbol “TRUL” and trade on the OTCQX market under the symbol “TCNNF”. </p>
<p> <b> Forward-Looking Statements </b> </p>
<p> This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding the intended use of the net proceeds of the Offering, the listing of the subordinate voting shares of the Company on the CSE or inferring the future business, operations, financial performance, prospects, capital raising initiatives and other plans, intentions, expectations, estimates, and beliefs of the Company. Words such as “expects”, “continue”, “will”, “anticipates” and “intends” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current projections and expectations about future events and financial trends that management believes might affect its financial condition, results of operations, business strategy and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate. </p>
<p> Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Such factors include, among others: the risks and uncertainties identified in the (final) short form base shelf prospectus of the Company and the Registration Statement and in the Company’s other reports and filings with the applicable Canadian securities regulators and the SEC. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws. </p>
<p> The CSE has not reviewed, approved or disapproved the content of this news release. </p>
<p> SOURCE Trulieve Cannabis Corp. </p>
<p> <img alt="" class="lazy" data-src="https://rt.newswire.ca/rt.gif?NewsItemId=C5477&Transmission_Id=202104120925CANADANWCANADAPR_C5477&DateId=20210412" data-srcset="" src="https://rt.newswire.ca/rt.gif?NewsItemId=C5477&Transmission_Id=202104120925CANADANWCANADAPR_C5477&DateId=20210412" srcset=""/></p>
<p> <img alt="Cision" class="lazy" data-src="https://c212.net/c/img/favicon.png?sn=C5477&sd=2021-04-12" data-srcset="" height="12" src="https://c212.net/c/img/favicon.png?sn=C5477&sd=2021-04-12" srcset="" title="Cision" width="12"/> View original content: <a href="http://www.newswire.ca/en/releases/archive/April2021/12/c5477.html" rel="noopener noreferrer" target="_blank"> http://www.newswire.ca/en/releases/archive/April2021/12/c5477.html </a> </p>
</div>
</div>
<p>News Provided by Canada Newswire via QuoteMedia</p>
<p></p><div class="cp-text-ad"><div class="row text-ad-ofie">
<div class="ad-image large-4 medium-4 small-12 columns"><a href="https://investingnews.com/free-report-online/cannabis-ma-will-the-fortune-500-join-the-party/" id="Type: Outlook, Category: Cannabis Investing">
<img alt="Cannabis Free Report Cover" class="hide-for-small-only" src="https://cdn.investingnews.com/app/uploads/2021/03/Cannabis-MA-2.0-Will-the-Fortune-500-Join-the-Party-3D-min.jpg" title="Profiting from the Cannabis Industry"/></a></div>
<div class="ad-copy large-8 medium-8 small-11 columns">
<h2 align="center" class="ofie">Cannabis - Will The Fortune 500 Join The Party?</h2>
<h5 align="center" class="subheadline">Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!</h5>
<div align="center"><a class="button red radius" href="https://investingnews.com/free-report-online/cannabis-ma-will-the-fortune-500-join-the-party/" id="Type: Outlook, Category: Cannabis Investing"> Grab Your Report Today! </a></div>
</div>
<!-- end large-8 -->
</div></div>
Keep reading...
Show less
Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or “ Ayurcann ”), is pleased to announce that the Company intends to complete a non-brokered private placement (the “Financing” ) of up to 2,645,503 units (the “Units” ) at a price of $0.189 per Unit. Each Unit will consist of one common share ( “Common Share” ) of the Company and one-half of a common share purchase warrant ( “Warrant” ), with each whole Warrant entitling the holder to acquire one additional Common Share at an exercise price of $0.38 per Common Share for a period of 36 months from the closing date ( “Closing Date” ) of the Financing, for gross proceeds of up to $500,000 .
The Company will have an option, prior to the closing date, to upsize the offering with the sale of an additional 25% of Units, accounting to aggregate proceeds of up to $625,000.
<p align="justify"> Certain insiders of the Company may participate in the Financing. The Company may pay a commission in cash equal to 6% of the value of select proceeds raised under the Financing, specifically excluding any funds raised from insiders. </p>
<p align="justify"> The Company will use the gross proceeds of the Financing for their Pickering facility Phase 2 expansion, which, when such expansion is complete, is estimated to increase the Company’s annual extraction capacity from 200,000 kgs to 300,000 kgs once complete. </p>
<p align="justify"> Closing Date of the Financing is expected to occur on or around April 22, 2021, and is subject to all regulatory approvals including the approval of the Canadian Securities Exchange. The securities issued in connection with this Financing will be subject to a four-month and one day hold period from the date of closing in accordance with applicable securities legislation. </p>
<p> <strong> For further information, please contact: </strong> <br/> Igal Sudman, Chairman, Chief Executive Officer and Corporate Secretary <br/> Ayurcann Holdings Corp. <br/> Tel: 416-720-6264 <br/> Emial: <a href="https://www.globenewswire.com/Tracker?data=B3jUJ3-Shfk0h2QZCmn97Y37P4up--8ZLyCOuCVMrTLfa0KCxHQvdUIreNDDk_8R1hEeOxZkMxCUI5y7l_7U2g==" rel="nofollow noopener noreferrer" target="_blank"> igal@xtrx.ca </a> </p>
<p> <strong> Investor Relations: </strong> <br/> Ryan Bilodeau <br/> Tel: 416-910-1440 <br/> Email: <a href="https://www.globenewswire.com/Tracker?data=fd2Z2iVTdM5ay8Lm3Y9Zez9jmrdVp9Y18h7wEG1FB5TCXcvsbzYWC8YpUteUJwdJ6heRCTNcpPFuKcLM6eSERueUnSMlElxYZVJHX4S-uSE=" rel="nofollow noopener noreferrer" target="_blank"> ryan@cascadeventures.co </a> </p>
<p> <em> Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release. </em> </p>
<p> <strong> About Ayurcann Holdings Corp.: </strong> <br/> Ayurcann is a leading post harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada. Ayurcann is focused on being the partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing. </p>
<p align="justify"> <em> Neither the CSE nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release. </em> </p>
<p align="justify"> <em> Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward- looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements, including: listing of the common shares of the Company on the CSE. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. </em> </p>
<p align="justify"> <em> Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include failure to obtain regulatory approval, the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements. </em> </p>
<p> <img class="lazy" data-src="https://www.globenewswire.com/newsroom/ti?nf=ODIxNTIyOSM0MTE2MTY1IzIwODI0NjU=" data-srcset="" height="1" src="https://www.globenewswire.com/newsroom/ti?nf=ODIxNTIyOSM0MTE2MTY1IzIwODI0NjU=" srcset="" width="1"/><br/><img class="lazy" data-src="https://ml.globenewswire.com/release/track/0aa20773-3809-4e0e-9562-46c8ae0e725b" data-srcset="" height="1" referrerpolicy="no-referrer-when-downgrade" src="https://ml.globenewswire.com/release/track/0aa20773-3809-4e0e-9562-46c8ae0e725b" srcset="" width="1"/></p>
<p> <a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/da18165f-e843-4458-93fe-034645b88faa" rel="noopener noreferrer" target="_blank"> <img alt="Primary Logo" border="0" class="lazy" data-src="https://ml.globenewswire.com/media/da18165f-e843-4458-93fe-034645b88faa/small/ayurcannlogo-jpg.jpg" data-srcset="" height="141" src="https://ml.globenewswire.com/media/da18165f-e843-4458-93fe-034645b88faa/small/ayurcannlogo-jpg.jpg" srcset="" width="150"/></a> </p>
</div>
<p>News Provided by GlobeNewswire via QuoteMedia</p>
<p></p>
Keep reading...
Show less
Lobe invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce that it has been invited to present at the Emerging Growth Conference on April 14, 2021.
<p>This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s CEO and Director, Philip Young in real time.</p>
<p>Lobe will be presenting at 10:30 am Eastern time for 45 minutes. Mr. Young will provide a full presentation and will be available for questions after his presentation.</p>
<p>Interested participants are encouraged to register in advance at: <br/><a href="https://www.newsfilecorp.com/redirect/8QDjTyPEG" rel="noopener noreferrer" target="_blank">https://goto.webcasts.com/starthere.jsp?ei=1451311&tp_key=5b36cea9ad&sti=lobe</a></p>
<p>An archived webcast will also be made available on <a href="https://www.newsfilecorp.com/redirect/yyKOtkYLW" rel="noopener noreferrer" target="_blank">EmergingGrowth.com</a> after the live event.</p>
<p><b>About the Emerging Growth Conference</b></p>
<p>The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.</p>
<p>The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts.</p>
<p>All sessions will be conducted through video webcasts and will take place in the Eastern time zone.</p>
<p><b>About <a href="https://investingnews.com/company-profiles/lobe-sciences-cse-lobe/">Lobe Sciences Ltd.</a></b></p>
<p>Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.</p>
<p><b>For further information please contact: </b></p>
<p><b><a href="https://investingnews.com/company-profiles/lobe-sciences-cse-lobe/">Lobe Sciences Ltd.</a></b><br/>Philip J Young, CEO<br/><a href="mailto:info@lobesciences.com" rel="noopener noreferrer" target="_blank">info@lobesciences.com</a><br/>Tel: (949) 505-5623</p>
<p><i>THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.</i></p>
<p><i><b>Disclaimer for Forward Looking Statements </b></i></p>
<p><i>This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, the development of innovative devices and delivery mechanisms to improve mental health and wellness are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at <a href="https://www.newsfilecorp.com/redirect/1VYNie3pz" rel="noopener noreferrer" target="_blank">www.sedar.com</a>. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.</i></p>
<p id="corporateNewsLogoContainer"><img alt="Corporate Logo" class="lazy" data-src="https://orders.newsfilecorp.com/files/6461/80019_ab700a7f5429aa19_logo.jpg" data-srcset="" id="corporateNewsLogo" src="https://orders.newsfilecorp.com/files/6461/80019_ab700a7f5429aa19_logo.jpg" srcset=""/></p>
<p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://www.newsfilecorp.com/redirect/AwQLFaex7" rel="noopener noreferrer" target="_blank">https://www.newsfilecorp.com/release/80019</a></p>
<p><img alt="" class="lazy" data-src="https://www.newsfilecorp.com/newsinfo/80019/310" data-srcset="" src="https://www.newsfilecorp.com/newsinfo/80019/310" srcset=""/></p>
</div>
<p>News Provided by Newsfile via QuoteMedia</p>
<p></p><div class="stock-information sidebar-block">
<div class="title">Request an Investor Kit: <h3>Lobe Sciences</h3></div>
<form action="https://investingnews.com" id="subscribe_per_category" method="POST">
<div class="form-column left">
<input name="profiles_only" type="hidden" value="yes"/><input name="subscription_form" type="hidden" value="yes"/><input name="subscribe_company_profile_form" type="hidden" value="1"/><input name="source" type="hidden" value="https://investingnews.com/news/cannabis-investing/lobe-sciences-to-present-at-the-emerging-growth-conference-on-april-14-2021/"/><input class="referrer" name="referral_url" type="hidden" value=""/><input name="form_name" type="hidden" value="subscribe_cprofile_use_posts"/><input class="referrer" name="referral_url" type="hidden" value=""/><input name="cprofiles[]" type="hidden" value="Tzo4OiJzdGRDbGFzcyI6NDp7czoyOiJpZCI7czozNjoiODY3MWZiY2MtYjE5MS01ZmQ2LWM0ODktNWZiMmE5NTNmZjcxIjtzOjQ6Im5hbWUiO3M6MTM6IkxvYmUgU2NpZW5jZXMiO3M6NDoid3BpZCI7czo5OiIxMDE1OTE5NjUiO3M6MzoidXJsIjtzOjA6IiI7fQ=="/><input class="form-control" id="FirstName" name="first_name" placeholder="First Name" required="" type="text" value=""/><input class="form-control" id="LastName" name="last_name" placeholder="Last Name" required="" type="text" value=""/><input class="form-control" id="email" name="email" placeholder="Email" required="" type="email" value=""/><input class="form-control" id="phone" name="user_phone" pattern="[\+\s0-9]{3,15}" placeholder="Phone" title="Telephone number. Only digits and space signs are allowed" type="tel" value=""/></div>
<div class="form-column right">
<div class="extra-input">
<input id="AccreditedInvestor" name="accredited_investor" type="checkbox"/><label class="checkbox-label" for="AccreditedInvestor">
Include me in the <b>Accredited Investor</b> email list
<span class="help">
<i aria-hidden="true" class="fa fa-question-circle"></i>
<div class="help-box bigger">
Some investment opportunities are limited to accredited investors. Whether you are an accredited investor or not depends on where you live and other criteria. For full details go to https://investingnews.com/accredited-investor-definition/ or search for "accredited investor" in the search bar above.
</div>
</span>
</label>
</div>
<div class="more">
<input class="btn btn-primary" type="submit" value="Get More information"/></div>
<p class="legend">By completing this form, you are giving consent to receive communication from Lobe Sciences using the contact information you provide. And remember you can unsubscribe at any time.</p>
</div>
</form>
</div>
Keep reading...
Show less
Nextleaf Solutions Receives Amendment to Standard Processing Licence to Allow for Direct to Province Sales
April 12 | 2021
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to announce that its wholly-owned subsidiary, Nextleaf Labs Ltd. (“Nextleaf Labs”), has received an amendment to its existing Standard Cannabis Processing Licence from Health Canada (the “Amendment” or the “Amended Licence”) that authorizes the sale of cannabis extracts, edibles, and topical products, directly to provincially-authorized distributors and retailers across Canada.
<p>Cannot view this video? Visit:<br/><a href="https://www.newsfilecorp.com/redirect/PyQ1cOe73" rel="noopener noreferrer" target="_blank">https://www.youtube.com/watch?v=B3fCQ0fyHVc</a></p>
<p>The Amendment allows Nextleaf Labs to offer additional value-added services to its partners with a quicker and more seamless path to market. Furthermore, the Amended Licence provides Nextleaf with the necessary flexibility to add another revenue stream outside of the business-to-business market by launching its own house brand should the Company deem it accretive.</p>
<p>“The receipt of this licence amendment marks a significant milestone for Nextleaf, our commercial partners, and our investors,” said Nextleaf CEO, Paul Pedersen. “The sales licence helps Nextleaf service our partners more efficiently. Speed-to-market and the ability to test products effectively are often just as important to our partners as the price per molecule. This sales amendment, alongside our recently announced research licence amendment, and our unrivaled technology positions Nextleaf as a top tier extraction partner. Lastly, the amendment allows us to create and manufacture our own brands and add to our bottom-line revenue as the industry waits for market equilibrium in the extracts segment.”</p>
<p>Nextleaf’s proprietary closed-loop automated extraction refinery, capable of processing up to 600 kilograms of cannabis or hemp biomass daily with only 2-3 operators per shift, is located at Nextleaf Labs in Metro Vancouver, British Columbia. </p>
<p><b>Nextleaf Issues Shares </b></p>
<p>Nextleaf has issued an aggregate of 45,283 common shares at a price of $0.265 per share, representing an aggregate value of $12,000, to a non-executive employee of the Company.</p>
<p><b>About Nextleaf®</b></p>
<p>Nextleaf is an innovative cannabis processor that owns one of the largest portfolios of U.S. patents for the extraction, distillation, and delivery of cannabinoids. Through its wholly-owned subsidiary Nextleaf Labs Ltd, a Health Canada licensed Standard Processor, the Company is a low-cost producer of cannabis distillate and private label THC & CBD oils. Nextleaf’s proprietary closed-loop automated extraction plant in Metro Vancouver has a design capacity to process 600 kilograms of dried cannabis into oil per day. The Company owns 12 U.S. patents and has been issued over 70 patents globally. Nextleaf is developing delivery technology through its Health Canada Research Licence with sensory evaluation of cannabis via human testing. The Company’s patent pending Rapid Emulsion Technology by OILS™ powers differentiated ingestible cannabis products. </p>
<p><a href="https://investingnews.com/company-profiles/nextleaf-solutions-cse:oils/">Nextleaf Solutions</a> trades as <a href="https://www.newsfilecorp.com/redirect/wexntbRLN" rel="noopener noreferrer" target="_blank">OILS on the Canadian Securities Exchange</a>, <a href="https://www.newsfilecorp.com/redirect/goeATMqKW" rel="noopener noreferrer" target="_blank">OILFF on the OTCQB Market in the United States</a>, and <a href="https://www.newsfilecorp.com/redirect/pWenhwGN7" rel="noopener noreferrer" target="_blank">L0MA on the Frankfurt Stock Exchange</a>.</p>
<p>Follow OILS across social media platforms: <a href="https://www.newsfilecorp.com/redirect/YrV1spgag" rel="noopener noreferrer" target="_blank">Twitter</a>, <a href="https://www.newsfilecorp.com/redirect/0rqPsrDoZ" rel="noopener noreferrer" target="_blank">LinkedIn</a>, <a href="https://www.newsfilecorp.com/redirect/RAk1FABDL" rel="noopener noreferrer" target="_blank">Facebook</a>, and <a href="https://www.newsfilecorp.com/redirect/WX31FBPqz" rel="noopener noreferrer" target="_blank">Instagram</a>.<br/><a href="https://investingnews.com/company-profiles/nextleaf-solutions-cse:oils/" rel="noopener noreferrer" target="_blank">www.nextleafsolutions.com</a></p>
<p>For more information please contact:<br/>Jason McBride<br/>604-283-2301 (ext. 219)<br/><a href="mailto:investors@nextleafsolutions.com" rel="noopener noreferrer" target="_blank">investors@nextleafsolutions.com</a></p>
<p>On behalf of the Board of Directors of the Company,</p>
<p>Paul Pedersen, CEO</p>
<p>Certain statements contained in this press release constitute “forward-looking statements”. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company’s ability to capitalize on its IP portfolio,<b> </b>the Company’s strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company’s MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved the contents of this press release.</p>
<p id="corporateNewsLogoContainer"><img alt="Corporate Logo" class="lazy" data-src="https://orders.newsfilecorp.com/files/5347/80103_fa96a71df4c788e8_logo.jpg" data-srcset="" id="corporateNewsLogo" src="https://orders.newsfilecorp.com/files/5347/80103_fa96a71df4c788e8_logo.jpg" srcset=""/></p>
<p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://www.newsfilecorp.com/redirect/n0eni7gE5" rel="noopener noreferrer" target="_blank">https://www.newsfilecorp.com/release/80103</a></p>
<p><img alt="" class="lazy" data-src="https://www.newsfilecorp.com/newsinfo/80103/310" data-srcset="" src="https://www.newsfilecorp.com/newsinfo/80103/310" srcset=""/></p>
</div>
<p>News Provided by Newsfile via QuoteMedia</p>
<p></p><div class="stock-information sidebar-block">
<div class="title">Request an Investor Kit: <h3>Nextleaf Solutions</h3></div>
<form action="https://investingnews.com" id="subscribe_per_category" method="POST">
<div class="form-column left">
<input name="profiles_only" type="hidden" value="yes"/><input name="subscription_form" type="hidden" value="yes"/><input name="subscribe_company_profile_form" type="hidden" value="1"/><input name="source" type="hidden" value="https://investingnews.com/news/cannabis-investing/nextleaf-solutions-receives-amendment-to-standard-processing-licence-to-allow-for-direct-to-province-sales/"/><input class="referrer" name="referral_url" type="hidden" value=""/><input name="form_name" type="hidden" value="subscribe_cprofile_use_posts"/><input class="referrer" name="referral_url" type="hidden" value=""/><input name="cprofiles[]" type="hidden" value="Tzo4OiJzdGRDbGFzcyI6NDp7czoyOiJpZCI7czozNjoiMTkyMTg4M2YtM2U2NS0wZjcxLWZkOTUtNWM5M2E3ODE4MDBjIjtzOjQ6Im5hbWUiO3M6MTg6Ik5leHRsZWFmIFNvbHV0aW9ucyI7czo0OiJ3cGlkIjtzOjk6IjEwMTQ5NDg0MSI7czozOiJ1cmwiO3M6MDoiIjt9"/><input class="form-control" id="FirstName" name="first_name" placeholder="First Name" required="" type="text" value=""/><input class="form-control" id="LastName" name="last_name" placeholder="Last Name" required="" type="text" value=""/><input class="form-control" id="email" name="email" placeholder="Email" required="" type="email" value=""/><input class="form-control" id="phone" name="user_phone" pattern="[\+\s0-9]{3,15}" placeholder="Phone" title="Telephone number. Only digits and space signs are allowed" type="tel" value=""/></div>
<div class="form-column right">
<div class="extra-input">
<input id="AccreditedInvestor" name="accredited_investor" type="checkbox"/><label class="checkbox-label" for="AccreditedInvestor">
Include me in the <b>Accredited Investor</b> email list
<span class="help">
<i aria-hidden="true" class="fa fa-question-circle"></i>
<div class="help-box bigger">
Some investment opportunities are limited to accredited investors. Whether you are an accredited investor or not depends on where you live and other criteria. For full details go to https://investingnews.com/accredited-investor-definition/ or search for "accredited investor" in the search bar above.
</div>
</span>
</label>
</div>
<div class="more">
<input class="btn btn-primary" type="submit" value="Get More information"/></div>
<p class="legend">By completing this form, you are giving consent to receive communication from Nextleaf Solutions using the contact information you provide. And remember you can unsubscribe at any time.</p>
</div>
</form>
</div>
Keep reading...
Show less